183 related articles for article (PubMed ID: 29186439)
1. Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context.
Patrono C
Cardiovasc Res; 2017 Dec; 113(14):e61-e63. PubMed ID: 29186439
[No Abstract] [Full Text] [Related]
2. Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?
Boden WE; Bhatt DL
Circulation; 2018 Aug; 138(9):858-860. PubMed ID: 30354448
[No Abstract] [Full Text] [Related]
3. Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events.
Med Lett Drugs Ther; 2018 Dec; 60(1561):196-197. PubMed ID: 30653475
[No Abstract] [Full Text] [Related]
4. Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial.
Nicholls SJ; Nelson AJ
Am J Cardiovasc Drugs; 2019 Aug; 19(4):343-348. PubMed ID: 30680652
[TBL] [Abstract][Full Text] [Related]
5. Aspirin dosing for atherosclerotic cardiovascular disease: should we be more ADAPTABLE?
Parker WAE; Storey RF
Cardiovasc Res; 2021 Aug; 117(10):e123-e125. PubMed ID: 34370832
[No Abstract] [Full Text] [Related]
6. Triple therapy: worth the risk?
Wernly B; Lichtenauer M; Hoppe UC; Lauten A; Navarese EP; Jung C
Minerva Med; 2018 Oct; 109(5):403-405. PubMed ID: 30338683
[No Abstract] [Full Text] [Related]
7. [The COMPASS study].
Calabrò P; Gragnano F; Visconti LO
G Ital Cardiol (Rome); 2018 Jan; 19(1):1-7. PubMed ID: 29451504
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
Liang Y; Zhu J; Liu L; Anand SS; Connolly SJ; Bosch J; Guzik TJ; O'Donnell M; Dagenais GR; Fox KA; Shestakovska O; Berkowitz SD; Muehlhofer E; Keller L; Yusuf S; Eikelboom JW;
Cardiovasc Res; 2021 Feb; 117(3):942-949. PubMed ID: 32289159
[TBL] [Abstract][Full Text] [Related]
9. Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin.
Eikelboom JW; Bosch JJ; Connolly SJ; Shestakovska O; Dagenais GR; Hart RG; Leong DP; O'Donnell M; Fox KAA; Bhatt DL; Cairns JA; Tasto C; Berkowitz SD; Cook Bruns N; Muehlhofer E; Diaz R; Maggioni AP; Yusuf S
J Am Coll Cardiol; 2019 Sep; 74(12):1519-1528. PubMed ID: 31537259
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban in peripheral artery disease: The new kid on the block?
Hussain MA; Verma S; Al-Omran M
J Vasc Surg; 2018 Mar; 67(3):985-986. PubMed ID: 29477208
[No Abstract] [Full Text] [Related]
11. Patients with Peripheral Artery Disease in the COMPASS Trial.
Kruger PC; Anand SS; de Vries TAC; Eikelboom JW
Eur J Vasc Endovasc Surg; 2018 Dec; 56(6):772-773. PubMed ID: 30213508
[No Abstract] [Full Text] [Related]
12. Role of rivaroxaban in the prevention of atherosclerotic events.
Sanmartín M; Bellmunt S; Cosín-Sales J; García-Moll X; Riera-Mestre A; Almendro-Delia M; Hernández JL; Lozano F; Mazón P; Suarez Fernández C
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):771-780. PubMed ID: 31269825
[No Abstract] [Full Text] [Related]
13. Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition.
González-Juanatey JR; Almendro-Delia M; Cosín-Sales J; Bellmunt-Montoya S; Gómez-Doblas JJ; Riambau V; García-Moll X; García-Alegría J; Hernández JL; Lozano FS; Suarez Fernández C
Expert Rev Clin Pharmacol; 2020 Jul; 13(7):695-706. PubMed ID: 32434452
[TBL] [Abstract][Full Text] [Related]
14. Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy.
Ameriso SF; Amarenco P; Pearce LA; Perera KS; Ntaios G; Lang W; Bereczki D; Uchiyama S; Kasner SE; Yoon BW; Lavados P; Firstenfeld A; Mikulik R; Povedano GP; Ferrari J; Mundl H; Berkowitz SD; Connolly SJ; Hart RG
J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104936. PubMed ID: 32689594
[TBL] [Abstract][Full Text] [Related]
15. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
Anand SS; Hiatt W; Dyal L; Bauersachs R; Berkowitz SD; Branch KRH; Debus S; Fox KAA; Liang Y; Muehlhofer E; Nehler M; Haskell LP; Patel M; Szarek M; Yusuf S; Eikelboom J; Bonaca MP
Eur J Prev Cardiol; 2022 May; 29(5):e181-e189. PubMed ID: 34463737
[TBL] [Abstract][Full Text] [Related]
16. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
Moayyedi P; Eikelboom JW; Bosch J; Connolly SJ; Dyal L; Shestakovska O; Leong D; Anand SS; Störk S; Branch KRH; Bhatt DL; Verhamme PB; O'Donnell M; Maggioni AP; Lonn EM; Piegas LS; Ertl G; Keltai M; Bruns NC; Muehlhofer E; Dagenais GR; Kim JH; Hori M; Steg PG; Hart RG; Diaz R; Alings M; Widimsky P; Avezum A; Probstfield J; Zhu J; Liang Y; Lopez-Jaramillo P; Kakkar AK; Parkhomenko AN; Ryden L; Pogosova N; Dans AL; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik TJ; Vinereanu D; Tonkin AM; Lewis BS; Felix C; Yusoff K; Metsarinne KP; Fox KAA; Yusuf S;
Gastroenterology; 2019 Sep; 157(3):682-691.e2. PubMed ID: 31152740
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
Weitz JI; Lensing AWA; Prins MH; Bauersachs R; Beyer-Westendorf J; Bounameaux H; Brighton TA; Cohen AT; Davidson BL; Decousus H; Freitas MCS; Holberg G; Kakkar AK; Haskell L; van Bellen B; Pap AF; Berkowitz SD; Verhamme P; Wells PS; Prandoni P;
N Engl J Med; 2017 Mar; 376(13):1211-1222. PubMed ID: 28316279
[TBL] [Abstract][Full Text] [Related]
18. A look back: the quest for thrombosis in heart failure continues after COMMANDER HF.
Filippatos G; Farmakis D
Cardiovasc Res; 2019 Nov; 115(13):e140-e142. PubMed ID: 31638158
[No Abstract] [Full Text] [Related]
19. Rivaroxaban with or without aspirin for prevention of cardiovascular disease.
Kruger PC; Eikelboom JW; Yusuf S
Coron Artery Dis; 2018 Aug; 29(5):361-365. PubMed ID: 29346127
[No Abstract] [Full Text] [Related]
20. Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?
Fox KAA; Eikelboom JW; Anand SS; Bhatt DL; Bosch J; Connolly SJ; Harrington RA; Steg PG; Yusuf S
Eur Heart J; 2019 May; 40(18):1466-1471. PubMed ID: 29945212
[No Abstract] [Full Text] [Related]
[Next] [New Search]
